Peter Schotte

This inventor holds 20 USPTO granted patents and 9 published patent applications, plus 4 CIPO patents and 6 EPO patents. Top assignees: Ablynx N.v., Sanofi. Active years: 2015-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Peter Schotte. Retrieved from https://idiyas.com/inventor/peter-schotte

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 20 (Patent Applications = 9)

% Patents Active = 100.0

CIPO Patents = 4 (Patent Applications = 2)

EPO Patents = 6 (Patent Applications = 13)

Average Co-Inventor Count = 5.3

ph-index = 3

Forward Citations = 39(Granted Patents)

Company Filing History:

where one patent can have more than one assignee

Years Active: 2015-2026

Loading Chart...

20 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12709646 - POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING GLYPICAN-3 AND T CELL RECEPTOR (2026-08-18),

2. 12662525 - TECHNIQUES FOR PREDICTING, DETECTING AND REDUCING ASPECIFIC PROTEIN INTERFERENCE IN ASSAYS INVOLVING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS (2026-06-23),

3. 12630609 - TECHNIQUES FOR PREDICTING, DETECTING AND REDUCING ASPECIFIC PROTEIN INTERFERENCE IN ASSAYS INVOLVING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS (2026-05-19),

4. 12516105 - TECHNIQUES FOR PREDICTING, DETECTING AND REDUCING ASPECIFIC PROTEIN INTERFERENCE IN ASSAYS INVOLVING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS (2026-01-06),

5. 12384835 - Cysteine linked nanobody dimers (2025-08-12),

6. 12116607 - Method for the production of domain antibodies (2024-10-15),

7. 12006352 - Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains (2024-06-11),

8. 11932702 - Polypeptides comprising immunoglobulin single variable domains targeting glypican-3 and T cell receptor (2024-03-19),

9. 11851480 - Method for the production of immunoglobulin single variable domains (2023-12-26),

10. 11644471 - Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains (2023-05-09),

11. 11426468 - Cysteine linked nanobody dimers (2022-08-30),

12. 11192938 - Serum albumin binding proteins containing immunoglobulin single variable domains (2021-12-07),

13. 11192937 - Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains (2021-12-07),

14. 11021544 - Nanobody dimers linked via C-terminally engineered cysteins (2021-06-01),

15. 10975141 - Method for the production of immunoglobulin single variable domains (2021-04-13),

Title: Innovations of Peter Schotte

Introduction

Peter Schotte is a notable inventor based in De Pinte, Belgium. He has made significant contributions to the field of biotechnology, particularly in the development of novel antibody technologies. With a total of 16 patents to his name, Schotte's work has advanced the understanding and application of immunoglobulin domains.

Latest Patents

Among his latest patents is the invention of cysteine linked nanobody dimers. This invention relates to dimers that comprise a first polypeptide and a second polypeptide, each containing at least one immunoglobulin single variable domain (ISVD) and a C-terminal extension with a cysteine moiety. The dimers are covalently linked via a disulfide bond, resulting in constructs that outperform benchmark constructs in various assays. Another significant patent is a method for the production of domain antibodies in yeast, which promotes the formation of disulfide bridges in the antibodies through the addition of oxidizing agents.

Career Highlights

Peter Schotte has worked with prominent companies in the biotechnology sector, including Ablynx N.V. and Sanofi. His experience in these organizations has allowed him to refine his skills and contribute to groundbreaking research and development in the field.

Collaborations

Throughout his career, Schotte has collaborated with notable colleagues such as Carlo Boutton and Bruno Dombrecht. These partnerships have fostered innovation and have been instrumental in the advancement of his projects.

Conclusion

Peter Schotte's contributions to biotechnology through his patents and collaborations highlight his role as a leading inventor in the field. His work continues to influence the development of new therapeutic technologies.

Profile summary based on public USPTO records.